nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—PDE4B—hematologic cancer	0.633	1	CbGaD
Roflumilast—PDE4D—lung—hematologic cancer	0.00154	0.11	CbGeAlD
Roflumilast—PDE4D—testis—hematologic cancer	0.00146	0.103	CbGeAlD
Roflumilast—PDE4B—hematopoietic system—hematologic cancer	0.0014	0.0996	CbGeAlD
Roflumilast—PDE4A—lung—hematologic cancer	0.00137	0.097	CbGeAlD
Roflumilast—PDE4A—testis—hematologic cancer	0.00129	0.0915	CbGeAlD
Roflumilast—PDE4B—gonad—hematologic cancer	0.00107	0.0757	CbGeAlD
Roflumilast—PDE4D—lymph node—hematologic cancer	0.00106	0.075	CbGeAlD
Roflumilast—PDE4A—lymph node—hematologic cancer	0.000934	0.0663	CbGeAlD
Roflumilast—PDE4B—blood—hematologic cancer	0.000928	0.066	CbGeAlD
Roflumilast—PDE4B—bone marrow—hematologic cancer	0.000898	0.0638	CbGeAlD
Roflumilast—PDE4B—lung—hematologic cancer	0.000814	0.0578	CbGeAlD
Roflumilast—PDE4B—testis—hematologic cancer	0.000768	0.0546	CbGeAlD
Roflumilast—PDE4B—lymph node—hematologic cancer	0.000557	0.0396	CbGeAlD
Roflumilast—Dyspepsia—Triamcinolone—hematologic cancer	7.32e-05	0.000263	CcSEcCtD
Roflumilast—Rash—Ifosfamide—hematologic cancer	7.32e-05	0.000263	CcSEcCtD
Roflumilast—Dermatitis—Ifosfamide—hematologic cancer	7.31e-05	0.000263	CcSEcCtD
Roflumilast—Dizziness—Irinotecan—hematologic cancer	7.29e-05	0.000262	CcSEcCtD
Roflumilast—Urticaria—Etoposide—hematologic cancer	7.28e-05	0.000262	CcSEcCtD
Roflumilast—Malaise—Prednisone—hematologic cancer	7.26e-05	0.000261	CcSEcCtD
Roflumilast—Rhinitis—Epirubicin—hematologic cancer	7.25e-05	0.000261	CcSEcCtD
Roflumilast—Abdominal pain—Etoposide—hematologic cancer	7.25e-05	0.000261	CcSEcCtD
Roflumilast—Urinary tract infection—Doxorubicin—hematologic cancer	7.25e-05	0.000261	CcSEcCtD
Roflumilast—Vertigo—Prednisone—hematologic cancer	7.23e-05	0.00026	CcSEcCtD
Roflumilast—Vomiting—Vincristine—hematologic cancer	7.2e-05	0.000259	CcSEcCtD
Roflumilast—Urticaria—Prednisolone—hematologic cancer	7.18e-05	0.000258	CcSEcCtD
Roflumilast—Asthenia—Cisplatin—hematologic cancer	7.18e-05	0.000258	CcSEcCtD
Roflumilast—Cardiac disorder—Methotrexate—hematologic cancer	7.17e-05	0.000258	CcSEcCtD
Roflumilast—Fatigue—Triamcinolone—hematologic cancer	7.17e-05	0.000258	CcSEcCtD
Roflumilast—Rash—Vincristine—hematologic cancer	7.14e-05	0.000257	CcSEcCtD
Roflumilast—Dermatitis—Vincristine—hematologic cancer	7.13e-05	0.000257	CcSEcCtD
Roflumilast—Connective tissue disorder—Epirubicin—hematologic cancer	7.11e-05	0.000256	CcSEcCtD
Roflumilast—Headache—Vincristine—hematologic cancer	7.09e-05	0.000255	CcSEcCtD
Roflumilast—Hepatobiliary disease—Doxorubicin—hematologic cancer	7.05e-05	0.000254	CcSEcCtD
Roflumilast—Nausea—Carmustine—hematologic cancer	7.04e-05	0.000253	CcSEcCtD
Roflumilast—Vomiting—Mitoxantrone—hematologic cancer	7.01e-05	0.000252	CcSEcCtD
Roflumilast—Vomiting—Irinotecan—hematologic cancer	7.01e-05	0.000252	CcSEcCtD
Roflumilast—Sinusitis—Doxorubicin—hematologic cancer	6.99e-05	0.000252	CcSEcCtD
Roflumilast—Immune system disorder—Methotrexate—hematologic cancer	6.98e-05	0.000251	CcSEcCtD
Roflumilast—Nausea—Alitretinoin—hematologic cancer	6.98e-05	0.000251	CcSEcCtD
Roflumilast—Mediastinal disorder—Methotrexate—hematologic cancer	6.97e-05	0.000251	CcSEcCtD
Roflumilast—Rash—Irinotecan—hematologic cancer	6.95e-05	0.00025	CcSEcCtD
Roflumilast—Rash—Mitoxantrone—hematologic cancer	6.95e-05	0.00025	CcSEcCtD
Roflumilast—Dermatitis—Mitoxantrone—hematologic cancer	6.94e-05	0.00025	CcSEcCtD
Roflumilast—Dermatitis—Irinotecan—hematologic cancer	6.94e-05	0.00025	CcSEcCtD
Roflumilast—Headache—Irinotecan—hematologic cancer	6.9e-05	0.000248	CcSEcCtD
Roflumilast—Headache—Mitoxantrone—hematologic cancer	6.9e-05	0.000248	CcSEcCtD
Roflumilast—Nausea—Ifosfamide—hematologic cancer	6.9e-05	0.000248	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Betamethasone—hematologic cancer	6.87e-05	0.000247	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	6.87e-05	0.000247	CcSEcCtD
Roflumilast—Myalgia—Prednisone—hematologic cancer	6.85e-05	0.000247	CcSEcCtD
Roflumilast—Feeling abnormal—Triamcinolone—hematologic cancer	6.85e-05	0.000247	CcSEcCtD
Roflumilast—Diarrhoea—Cisplatin—hematologic cancer	6.85e-05	0.000246	CcSEcCtD
Roflumilast—Anxiety—Prednisone—hematologic cancer	6.83e-05	0.000246	CcSEcCtD
Roflumilast—Vomiting—Gemcitabine—hematologic cancer	6.83e-05	0.000246	CcSEcCtD
Roflumilast—Insomnia—Dexamethasone—hematologic cancer	6.82e-05	0.000246	CcSEcCtD
Roflumilast—Insomnia—Betamethasone—hematologic cancer	6.82e-05	0.000246	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	6.81e-05	0.000245	CcSEcCtD
Roflumilast—Discomfort—Prednisone—hematologic cancer	6.77e-05	0.000244	CcSEcCtD
Roflumilast—Mental disorder—Methotrexate—hematologic cancer	6.77e-05	0.000244	CcSEcCtD
Roflumilast—Rash—Gemcitabine—hematologic cancer	6.77e-05	0.000244	CcSEcCtD
Roflumilast—Dermatitis—Gemcitabine—hematologic cancer	6.76e-05	0.000243	CcSEcCtD
Roflumilast—Hypersensitivity—Etoposide—hematologic cancer	6.75e-05	0.000243	CcSEcCtD
Roflumilast—Malnutrition—Methotrexate—hematologic cancer	6.73e-05	0.000242	CcSEcCtD
Roflumilast—Headache—Gemcitabine—hematologic cancer	6.73e-05	0.000242	CcSEcCtD
Roflumilast—Nausea—Vincristine—hematologic cancer	6.72e-05	0.000242	CcSEcCtD
Roflumilast—Cardiac disorder—Epirubicin—hematologic cancer	6.71e-05	0.000242	CcSEcCtD
Roflumilast—Rhinitis—Doxorubicin—hematologic cancer	6.71e-05	0.000241	CcSEcCtD
Roflumilast—Hypersensitivity—Prednisolone—hematologic cancer	6.66e-05	0.00024	CcSEcCtD
Roflumilast—Dyspepsia—Betamethasone—hematologic cancer	6.64e-05	0.000239	CcSEcCtD
Roflumilast—Dyspepsia—Dexamethasone—hematologic cancer	6.64e-05	0.000239	CcSEcCtD
Roflumilast—Urticaria—Triamcinolone—hematologic cancer	6.61e-05	0.000238	CcSEcCtD
Roflumilast—Dysgeusia—Methotrexate—hematologic cancer	6.59e-05	0.000237	CcSEcCtD
Roflumilast—Asthenia—Etoposide—hematologic cancer	6.58e-05	0.000237	CcSEcCtD
Roflumilast—Connective tissue disorder—Doxorubicin—hematologic cancer	6.58e-05	0.000237	CcSEcCtD
Roflumilast—Decreased appetite—Dexamethasone—hematologic cancer	6.56e-05	0.000236	CcSEcCtD
Roflumilast—Decreased appetite—Betamethasone—hematologic cancer	6.56e-05	0.000236	CcSEcCtD
Roflumilast—Nausea—Mitoxantrone—hematologic cancer	6.55e-05	0.000236	CcSEcCtD
Roflumilast—Nausea—Irinotecan—hematologic cancer	6.55e-05	0.000236	CcSEcCtD
Roflumilast—Immune system disorder—Epirubicin—hematologic cancer	6.53e-05	0.000235	CcSEcCtD
Roflumilast—Infection—Prednisone—hematologic cancer	6.53e-05	0.000235	CcSEcCtD
Roflumilast—Mediastinal disorder—Epirubicin—hematologic cancer	6.52e-05	0.000235	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Dexamethasone—hematologic cancer	6.51e-05	0.000234	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Betamethasone—hematologic cancer	6.51e-05	0.000234	CcSEcCtD
Roflumilast—Back pain—Methotrexate—hematologic cancer	6.51e-05	0.000234	CcSEcCtD
Roflumilast—Fatigue—Betamethasone—hematologic cancer	6.51e-05	0.000234	CcSEcCtD
Roflumilast—Fatigue—Dexamethasone—hematologic cancer	6.51e-05	0.000234	CcSEcCtD
Roflumilast—Nervous system disorder—Prednisone—hematologic cancer	6.44e-05	0.000232	CcSEcCtD
Roflumilast—Skin disorder—Prednisone—hematologic cancer	6.38e-05	0.00023	CcSEcCtD
Roflumilast—Nausea—Gemcitabine—hematologic cancer	6.38e-05	0.000229	CcSEcCtD
Roflumilast—Vomiting—Cisplatin—hematologic cancer	6.36e-05	0.000229	CcSEcCtD
Roflumilast—Mental disorder—Epirubicin—hematologic cancer	6.34e-05	0.000228	CcSEcCtD
Roflumilast—Rash—Cisplatin—hematologic cancer	6.31e-05	0.000227	CcSEcCtD
Roflumilast—Dermatitis—Cisplatin—hematologic cancer	6.3e-05	0.000227	CcSEcCtD
Roflumilast—Malnutrition—Epirubicin—hematologic cancer	6.3e-05	0.000227	CcSEcCtD
Roflumilast—Diarrhoea—Etoposide—hematologic cancer	6.27e-05	0.000226	CcSEcCtD
Roflumilast—Ill-defined disorder—Methotrexate—hematologic cancer	6.24e-05	0.000225	CcSEcCtD
Roflumilast—Feeling abnormal—Dexamethasone—hematologic cancer	6.22e-05	0.000224	CcSEcCtD
Roflumilast—Feeling abnormal—Betamethasone—hematologic cancer	6.22e-05	0.000224	CcSEcCtD
Roflumilast—Cardiac disorder—Doxorubicin—hematologic cancer	6.21e-05	0.000223	CcSEcCtD
Roflumilast—Tension—Epirubicin—hematologic cancer	6.18e-05	0.000222	CcSEcCtD
Roflumilast—Gastrointestinal pain—Dexamethasone—hematologic cancer	6.17e-05	0.000222	CcSEcCtD
Roflumilast—Gastrointestinal pain—Betamethasone—hematologic cancer	6.17e-05	0.000222	CcSEcCtD
Roflumilast—Dysgeusia—Epirubicin—hematologic cancer	6.17e-05	0.000222	CcSEcCtD
Roflumilast—Hypersensitivity—Triamcinolone—hematologic cancer	6.13e-05	0.00022	CcSEcCtD
Roflumilast—Nervousness—Epirubicin—hematologic cancer	6.12e-05	0.00022	CcSEcCtD
Roflumilast—Back pain—Epirubicin—hematologic cancer	6.09e-05	0.000219	CcSEcCtD
Roflumilast—Malaise—Methotrexate—hematologic cancer	6.07e-05	0.000218	CcSEcCtD
Roflumilast—Dizziness—Etoposide—hematologic cancer	6.06e-05	0.000218	CcSEcCtD
Roflumilast—Muscle spasms—Epirubicin—hematologic cancer	6.05e-05	0.000218	CcSEcCtD
Roflumilast—Immune system disorder—Doxorubicin—hematologic cancer	6.05e-05	0.000218	CcSEcCtD
Roflumilast—Vertigo—Methotrexate—hematologic cancer	6.05e-05	0.000218	CcSEcCtD
Roflumilast—Mediastinal disorder—Doxorubicin—hematologic cancer	6.03e-05	0.000217	CcSEcCtD
Roflumilast—Urticaria—Betamethasone—hematologic cancer	5.99e-05	0.000216	CcSEcCtD
Roflumilast—Urticaria—Dexamethasone—hematologic cancer	5.99e-05	0.000216	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.99e-05	0.000215	CcSEcCtD
Roflumilast—Dizziness—Prednisolone—hematologic cancer	5.98e-05	0.000215	CcSEcCtD
Roflumilast—Asthenia—Triamcinolone—hematologic cancer	5.97e-05	0.000215	CcSEcCtD
Roflumilast—Abdominal pain—Betamethasone—hematologic cancer	5.96e-05	0.000215	CcSEcCtD
Roflumilast—Abdominal pain—Dexamethasone—hematologic cancer	5.96e-05	0.000215	CcSEcCtD
Roflumilast—Nausea—Cisplatin—hematologic cancer	5.94e-05	0.000214	CcSEcCtD
Roflumilast—Insomnia—Prednisone—hematologic cancer	5.94e-05	0.000214	CcSEcCtD
Roflumilast—Mental disorder—Doxorubicin—hematologic cancer	5.86e-05	0.000211	CcSEcCtD
Roflumilast—Ill-defined disorder—Epirubicin—hematologic cancer	5.84e-05	0.00021	CcSEcCtD
Roflumilast—Vomiting—Etoposide—hematologic cancer	5.83e-05	0.00021	CcSEcCtD
Roflumilast—Malnutrition—Doxorubicin—hematologic cancer	5.83e-05	0.00021	CcSEcCtD
Roflumilast—Dyspepsia—Prednisone—hematologic cancer	5.78e-05	0.000208	CcSEcCtD
Roflumilast—Rash—Etoposide—hematologic cancer	5.78e-05	0.000208	CcSEcCtD
Roflumilast—Dermatitis—Etoposide—hematologic cancer	5.78e-05	0.000208	CcSEcCtD
Roflumilast—Headache—Etoposide—hematologic cancer	5.74e-05	0.000207	CcSEcCtD
Roflumilast—Myalgia—Methotrexate—hematologic cancer	5.73e-05	0.000206	CcSEcCtD
Roflumilast—Tension—Doxorubicin—hematologic cancer	5.72e-05	0.000206	CcSEcCtD
Roflumilast—Decreased appetite—Prednisone—hematologic cancer	5.71e-05	0.000206	CcSEcCtD
Roflumilast—Dysgeusia—Doxorubicin—hematologic cancer	5.71e-05	0.000205	CcSEcCtD
Roflumilast—Rash—Prednisolone—hematologic cancer	5.7e-05	0.000205	CcSEcCtD
Roflumilast—Dermatitis—Prednisolone—hematologic cancer	5.7e-05	0.000205	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.69e-05	0.000205	CcSEcCtD
Roflumilast—Malaise—Epirubicin—hematologic cancer	5.68e-05	0.000204	CcSEcCtD
Roflumilast—Fatigue—Prednisone—hematologic cancer	5.67e-05	0.000204	CcSEcCtD
Roflumilast—Headache—Prednisolone—hematologic cancer	5.66e-05	0.000204	CcSEcCtD
Roflumilast—Discomfort—Methotrexate—hematologic cancer	5.66e-05	0.000204	CcSEcCtD
Roflumilast—Nervousness—Doxorubicin—hematologic cancer	5.66e-05	0.000204	CcSEcCtD
Roflumilast—Vertigo—Epirubicin—hematologic cancer	5.66e-05	0.000204	CcSEcCtD
Roflumilast—Back pain—Doxorubicin—hematologic cancer	5.64e-05	0.000203	CcSEcCtD
Roflumilast—Constipation—Prednisone—hematologic cancer	5.62e-05	0.000202	CcSEcCtD
Roflumilast—Muscle spasms—Doxorubicin—hematologic cancer	5.6e-05	0.000202	CcSEcCtD
Roflumilast—Palpitations—Epirubicin—hematologic cancer	5.56e-05	0.0002	CcSEcCtD
Roflumilast—Dizziness—Triamcinolone—hematologic cancer	5.5e-05	0.000198	CcSEcCtD
Roflumilast—Infection—Methotrexate—hematologic cancer	5.46e-05	0.000196	CcSEcCtD
Roflumilast—Nausea—Etoposide—hematologic cancer	5.45e-05	0.000196	CcSEcCtD
Roflumilast—Feeling abnormal—Prednisone—hematologic cancer	5.41e-05	0.000195	CcSEcCtD
Roflumilast—Asthenia—Betamethasone—hematologic cancer	5.41e-05	0.000195	CcSEcCtD
Roflumilast—Asthenia—Dexamethasone—hematologic cancer	5.41e-05	0.000195	CcSEcCtD
Roflumilast—Ill-defined disorder—Doxorubicin—hematologic cancer	5.41e-05	0.000195	CcSEcCtD
Roflumilast—Nervous system disorder—Methotrexate—hematologic cancer	5.39e-05	0.000194	CcSEcCtD
Roflumilast—Gastrointestinal pain—Prednisone—hematologic cancer	5.37e-05	0.000193	CcSEcCtD
Roflumilast—Nausea—Prednisolone—hematologic cancer	5.37e-05	0.000193	CcSEcCtD
Roflumilast—Myalgia—Epirubicin—hematologic cancer	5.36e-05	0.000193	CcSEcCtD
Roflumilast—Anxiety—Epirubicin—hematologic cancer	5.34e-05	0.000192	CcSEcCtD
Roflumilast—Skin disorder—Methotrexate—hematologic cancer	5.33e-05	0.000192	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	5.32e-05	0.000192	CcSEcCtD
Roflumilast—Discomfort—Epirubicin—hematologic cancer	5.3e-05	0.000191	CcSEcCtD
Roflumilast—Vomiting—Triamcinolone—hematologic cancer	5.29e-05	0.00019	CcSEcCtD
Roflumilast—Malaise—Doxorubicin—hematologic cancer	5.25e-05	0.000189	CcSEcCtD
Roflumilast—Rash—Triamcinolone—hematologic cancer	5.24e-05	0.000189	CcSEcCtD
Roflumilast—Dermatitis—Triamcinolone—hematologic cancer	5.24e-05	0.000188	CcSEcCtD
Roflumilast—Vertigo—Doxorubicin—hematologic cancer	5.23e-05	0.000188	CcSEcCtD
Roflumilast—Urticaria—Prednisone—hematologic cancer	5.22e-05	0.000188	CcSEcCtD
Roflumilast—Headache—Triamcinolone—hematologic cancer	5.21e-05	0.000187	CcSEcCtD
Roflumilast—Abdominal pain—Prednisone—hematologic cancer	5.19e-05	0.000187	CcSEcCtD
Roflumilast—Diarrhoea—Betamethasone—hematologic cancer	5.16e-05	0.000186	CcSEcCtD
Roflumilast—Diarrhoea—Dexamethasone—hematologic cancer	5.16e-05	0.000186	CcSEcCtD
Roflumilast—Palpitations—Doxorubicin—hematologic cancer	5.15e-05	0.000185	CcSEcCtD
Roflumilast—Infection—Epirubicin—hematologic cancer	5.11e-05	0.000184	CcSEcCtD
Roflumilast—Nervous system disorder—Epirubicin—hematologic cancer	5.04e-05	0.000181	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5e-05	0.00018	CcSEcCtD
Roflumilast—Skin disorder—Epirubicin—hematologic cancer	4.99e-05	0.00018	CcSEcCtD
Roflumilast—Dizziness—Betamethasone—hematologic cancer	4.99e-05	0.00018	CcSEcCtD
Roflumilast—Dizziness—Dexamethasone—hematologic cancer	4.99e-05	0.00018	CcSEcCtD
Roflumilast—Insomnia—Methotrexate—hematologic cancer	4.97e-05	0.000179	CcSEcCtD
Roflumilast—Myalgia—Doxorubicin—hematologic cancer	4.96e-05	0.000178	CcSEcCtD
Roflumilast—Anxiety—Doxorubicin—hematologic cancer	4.94e-05	0.000178	CcSEcCtD
Roflumilast—Nausea—Triamcinolone—hematologic cancer	4.94e-05	0.000178	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.93e-05	0.000177	CcSEcCtD
Roflumilast—Discomfort—Doxorubicin—hematologic cancer	4.9e-05	0.000176	CcSEcCtD
Roflumilast—Hypersensitivity—Prednisone—hematologic cancer	4.84e-05	0.000174	CcSEcCtD
Roflumilast—Dyspepsia—Methotrexate—hematologic cancer	4.83e-05	0.000174	CcSEcCtD
Roflumilast—Vomiting—Dexamethasone—hematologic cancer	4.8e-05	0.000173	CcSEcCtD
Roflumilast—Vomiting—Betamethasone—hematologic cancer	4.8e-05	0.000173	CcSEcCtD
Roflumilast—Decreased appetite—Methotrexate—hematologic cancer	4.77e-05	0.000172	CcSEcCtD
Roflumilast—Rash—Dexamethasone—hematologic cancer	4.76e-05	0.000171	CcSEcCtD
Roflumilast—Rash—Betamethasone—hematologic cancer	4.76e-05	0.000171	CcSEcCtD
Roflumilast—Dermatitis—Betamethasone—hematologic cancer	4.75e-05	0.000171	CcSEcCtD
Roflumilast—Dermatitis—Dexamethasone—hematologic cancer	4.75e-05	0.000171	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.74e-05	0.000171	CcSEcCtD
Roflumilast—Fatigue—Methotrexate—hematologic cancer	4.73e-05	0.00017	CcSEcCtD
Roflumilast—Headache—Betamethasone—hematologic cancer	4.73e-05	0.00017	CcSEcCtD
Roflumilast—Headache—Dexamethasone—hematologic cancer	4.73e-05	0.00017	CcSEcCtD
Roflumilast—Infection—Doxorubicin—hematologic cancer	4.72e-05	0.00017	CcSEcCtD
Roflumilast—Asthenia—Prednisone—hematologic cancer	4.71e-05	0.00017	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.68e-05	0.000168	CcSEcCtD
Roflumilast—Nervous system disorder—Doxorubicin—hematologic cancer	4.66e-05	0.000168	CcSEcCtD
Roflumilast—Insomnia—Epirubicin—hematologic cancer	4.65e-05	0.000167	CcSEcCtD
Roflumilast—Skin disorder—Doxorubicin—hematologic cancer	4.62e-05	0.000166	CcSEcCtD
Roflumilast—Feeling abnormal—Methotrexate—hematologic cancer	4.53e-05	0.000163	CcSEcCtD
Roflumilast—Dyspepsia—Epirubicin—hematologic cancer	4.52e-05	0.000163	CcSEcCtD
Roflumilast—Diarrhoea—Prednisone—hematologic cancer	4.5e-05	0.000162	CcSEcCtD
Roflumilast—Gastrointestinal pain—Methotrexate—hematologic cancer	4.49e-05	0.000162	CcSEcCtD
Roflumilast—Nausea—Betamethasone—hematologic cancer	4.48e-05	0.000161	CcSEcCtD
Roflumilast—Nausea—Dexamethasone—hematologic cancer	4.48e-05	0.000161	CcSEcCtD
Roflumilast—Decreased appetite—Epirubicin—hematologic cancer	4.47e-05	0.000161	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.44e-05	0.00016	CcSEcCtD
Roflumilast—Fatigue—Epirubicin—hematologic cancer	4.43e-05	0.000159	CcSEcCtD
Roflumilast—Constipation—Epirubicin—hematologic cancer	4.39e-05	0.000158	CcSEcCtD
Roflumilast—Urticaria—Methotrexate—hematologic cancer	4.36e-05	0.000157	CcSEcCtD
Roflumilast—Dizziness—Prednisone—hematologic cancer	4.35e-05	0.000156	CcSEcCtD
Roflumilast—Abdominal pain—Methotrexate—hematologic cancer	4.34e-05	0.000156	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.33e-05	0.000156	CcSEcCtD
Roflumilast—Insomnia—Doxorubicin—hematologic cancer	4.3e-05	0.000155	CcSEcCtD
Roflumilast—Feeling abnormal—Epirubicin—hematologic cancer	4.23e-05	0.000152	CcSEcCtD
Roflumilast—Gastrointestinal pain—Epirubicin—hematologic cancer	4.2e-05	0.000151	CcSEcCtD
Roflumilast—Dyspepsia—Doxorubicin—hematologic cancer	4.19e-05	0.000151	CcSEcCtD
Roflumilast—Vomiting—Prednisone—hematologic cancer	4.18e-05	0.00015	CcSEcCtD
Roflumilast—Rash—Prednisone—hematologic cancer	4.14e-05	0.000149	CcSEcCtD
Roflumilast—Dermatitis—Prednisone—hematologic cancer	4.14e-05	0.000149	CcSEcCtD
Roflumilast—Decreased appetite—Doxorubicin—hematologic cancer	4.13e-05	0.000149	CcSEcCtD
Roflumilast—Headache—Prednisone—hematologic cancer	4.12e-05	0.000148	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.11e-05	0.000148	CcSEcCtD
Roflumilast—Fatigue—Doxorubicin—hematologic cancer	4.1e-05	0.000148	CcSEcCtD
Roflumilast—Urticaria—Epirubicin—hematologic cancer	4.08e-05	0.000147	CcSEcCtD
Roflumilast—Constipation—Doxorubicin—hematologic cancer	4.07e-05	0.000146	CcSEcCtD
Roflumilast—Abdominal pain—Epirubicin—hematologic cancer	4.06e-05	0.000146	CcSEcCtD
Roflumilast—Hypersensitivity—Methotrexate—hematologic cancer	4.05e-05	0.000146	CcSEcCtD
Roflumilast—Asthenia—Methotrexate—hematologic cancer	3.94e-05	0.000142	CcSEcCtD
Roflumilast—Feeling abnormal—Doxorubicin—hematologic cancer	3.92e-05	0.000141	CcSEcCtD
Roflumilast—Nausea—Prednisone—hematologic cancer	3.9e-05	0.00014	CcSEcCtD
Roflumilast—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.89e-05	0.00014	CcSEcCtD
Roflumilast—Hypersensitivity—Epirubicin—hematologic cancer	3.79e-05	0.000136	CcSEcCtD
Roflumilast—Urticaria—Doxorubicin—hematologic cancer	3.78e-05	0.000136	CcSEcCtD
Roflumilast—Abdominal pain—Doxorubicin—hematologic cancer	3.76e-05	0.000135	CcSEcCtD
Roflumilast—Diarrhoea—Methotrexate—hematologic cancer	3.76e-05	0.000135	CcSEcCtD
Roflumilast—Asthenia—Epirubicin—hematologic cancer	3.69e-05	0.000133	CcSEcCtD
Roflumilast—Dizziness—Methotrexate—hematologic cancer	3.63e-05	0.000131	CcSEcCtD
Roflumilast—Diarrhoea—Epirubicin—hematologic cancer	3.52e-05	0.000127	CcSEcCtD
Roflumilast—Hypersensitivity—Doxorubicin—hematologic cancer	3.5e-05	0.000126	CcSEcCtD
Roflumilast—Vomiting—Methotrexate—hematologic cancer	3.49e-05	0.000126	CcSEcCtD
Roflumilast—Rash—Methotrexate—hematologic cancer	3.46e-05	0.000125	CcSEcCtD
Roflumilast—Dermatitis—Methotrexate—hematologic cancer	3.46e-05	0.000124	CcSEcCtD
Roflumilast—Headache—Methotrexate—hematologic cancer	3.44e-05	0.000124	CcSEcCtD
Roflumilast—Asthenia—Doxorubicin—hematologic cancer	3.41e-05	0.000123	CcSEcCtD
Roflumilast—Dizziness—Epirubicin—hematologic cancer	3.4e-05	0.000122	CcSEcCtD
Roflumilast—Vomiting—Epirubicin—hematologic cancer	3.27e-05	0.000118	CcSEcCtD
Roflumilast—Nausea—Methotrexate—hematologic cancer	3.26e-05	0.000117	CcSEcCtD
Roflumilast—Diarrhoea—Doxorubicin—hematologic cancer	3.25e-05	0.000117	CcSEcCtD
Roflumilast—Rash—Epirubicin—hematologic cancer	3.24e-05	0.000117	CcSEcCtD
Roflumilast—Dermatitis—Epirubicin—hematologic cancer	3.24e-05	0.000116	CcSEcCtD
Roflumilast—Headache—Epirubicin—hematologic cancer	3.22e-05	0.000116	CcSEcCtD
Roflumilast—Dizziness—Doxorubicin—hematologic cancer	3.14e-05	0.000113	CcSEcCtD
Roflumilast—Nausea—Epirubicin—hematologic cancer	3.05e-05	0.00011	CcSEcCtD
Roflumilast—Vomiting—Doxorubicin—hematologic cancer	3.02e-05	0.000109	CcSEcCtD
Roflumilast—Rash—Doxorubicin—hematologic cancer	3e-05	0.000108	CcSEcCtD
Roflumilast—Dermatitis—Doxorubicin—hematologic cancer	3e-05	0.000108	CcSEcCtD
Roflumilast—Headache—Doxorubicin—hematologic cancer	2.98e-05	0.000107	CcSEcCtD
Roflumilast—Nausea—Doxorubicin—hematologic cancer	2.82e-05	0.000102	CcSEcCtD
Roflumilast—PDE4A—Signaling by GPCR—PIK3CB—hematologic cancer	2.2e-05	0.000292	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PDGFRA—hematologic cancer	2.19e-05	0.00029	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PRKCG—hematologic cancer	2.18e-05	0.000289	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—JAK1—hematologic cancer	2.18e-05	0.000289	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ESR1—hematologic cancer	2.17e-05	0.000287	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CD86—hematologic cancer	2.16e-05	0.000286	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—JAK2—hematologic cancer	2.14e-05	0.000284	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—FN1—hematologic cancer	2.14e-05	0.000284	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL2RA—hematologic cancer	2.14e-05	0.000284	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HES1—hematologic cancer	2.13e-05	0.000282	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL2—hematologic cancer	2.12e-05	0.000282	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TERT—hematologic cancer	2.11e-05	0.000281	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—BAD—hematologic cancer	2.11e-05	0.00028	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NFKBIA—hematologic cancer	2.11e-05	0.00028	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NCOR1—hematologic cancer	2.11e-05	0.00028	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NOTCH1—hematologic cancer	2.09e-05	0.000278	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FGF1—hematologic cancer	2.09e-05	0.000277	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CSF2—hematologic cancer	2.09e-05	0.000277	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PDGFB—hematologic cancer	2.06e-05	0.000274	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FOXO1—hematologic cancer	2.06e-05	0.000273	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—IL2—hematologic cancer	2.06e-05	0.000273	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PDGFRB—hematologic cancer	2.06e-05	0.000273	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CD80—hematologic cancer	2.05e-05	0.000272	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CG—hematologic cancer	2.05e-05	0.000271	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KIT—hematologic cancer	2.05e-05	0.000271	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—NRAS—hematologic cancer	2.05e-05	0.000271	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL2RA—hematologic cancer	2.04e-05	0.00027	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CB—hematologic cancer	2.04e-05	0.00027	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PDGFRA—hematologic cancer	2.02e-05	0.000268	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL2—hematologic cancer	2.02e-05	0.000268	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TSC2—hematologic cancer	2.02e-05	0.000268	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PRKCG—hematologic cancer	2.02e-05	0.000268	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—JAK1—hematologic cancer	2.02e-05	0.000268	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TERT—hematologic cancer	2.01e-05	0.000267	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PTPN11—hematologic cancer	2.01e-05	0.000267	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PDGFB—hematologic cancer	1.96e-05	0.000261	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—MAPK3—hematologic cancer	1.96e-05	0.00026	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CREB1—hematologic cancer	1.95e-05	0.000258	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—FGFR3—hematologic cancer	1.94e-05	0.000257	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—BRAF—hematologic cancer	1.92e-05	0.000255	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAPK14—hematologic cancer	1.92e-05	0.000255	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TSC2—hematologic cancer	1.92e-05	0.000255	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCL2—hematologic cancer	1.91e-05	0.000253	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL6R—hematologic cancer	1.9e-05	0.000252	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CREBBP—hematologic cancer	1.9e-05	0.000252	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ESR1—hematologic cancer	1.88e-05	0.00025	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL2RA—hematologic cancer	1.88e-05	0.00025	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL2—hematologic cancer	1.87e-05	0.000248	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TERT—hematologic cancer	1.86e-05	0.000247	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—FN1—hematologic cancer	1.86e-05	0.000247	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—FGFR3—hematologic cancer	1.85e-05	0.000245	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—BAD—hematologic cancer	1.84e-05	0.000244	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NFKBIA—hematologic cancer	1.84e-05	0.000244	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAPK14—hematologic cancer	1.83e-05	0.000243	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NOTCH1—hematologic cancer	1.82e-05	0.000242	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PDGFB—hematologic cancer	1.82e-05	0.000241	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MAP2K1—hematologic cancer	1.81e-05	0.00024	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CD—hematologic cancer	1.8e-05	0.000239	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ESR1—hematologic cancer	1.79e-05	0.000238	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CD80—hematologic cancer	1.79e-05	0.000237	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PIK3CA—hematologic cancer	1.78e-05	0.000236	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KIT—hematologic cancer	1.78e-05	0.000236	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CG—hematologic cancer	1.78e-05	0.000236	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—NRAS—hematologic cancer	1.78e-05	0.000236	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TSC2—hematologic cancer	1.78e-05	0.000236	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—FN1—hematologic cancer	1.77e-05	0.000235	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—KRAS—hematologic cancer	1.76e-05	0.000234	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—BAD—hematologic cancer	1.75e-05	0.000232	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NFKBIA—hematologic cancer	1.75e-05	0.000232	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PTPN11—hematologic cancer	1.75e-05	0.000232	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NOTCH1—hematologic cancer	1.73e-05	0.00023	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—FGF2—hematologic cancer	1.72e-05	0.000229	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FGFR3—hematologic cancer	1.71e-05	0.000227	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—MAPK3—hematologic cancer	1.71e-05	0.000226	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CD80—hematologic cancer	1.7e-05	0.000225	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3R1—hematologic cancer	1.7e-05	0.000225	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CREB1—hematologic cancer	1.7e-05	0.000225	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KIT—hematologic cancer	1.7e-05	0.000225	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CG—hematologic cancer	1.7e-05	0.000225	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—NRAS—hematologic cancer	1.7e-05	0.000225	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAPK14—hematologic cancer	1.69e-05	0.000224	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—BRAF—hematologic cancer	1.67e-05	0.000222	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PTPN11—hematologic cancer	1.67e-05	0.000221	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ESR1—hematologic cancer	1.66e-05	0.00022	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCL2—hematologic cancer	1.66e-05	0.00022	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL6R—hematologic cancer	1.65e-05	0.000219	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CREBBP—hematologic cancer	1.65e-05	0.000219	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—JAK2—hematologic cancer	1.65e-05	0.000219	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FN1—hematologic cancer	1.64e-05	0.000218	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—MAPK3—hematologic cancer	1.62e-05	0.000215	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NFKBIA—hematologic cancer	1.62e-05	0.000215	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—BAD—hematologic cancer	1.62e-05	0.000215	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PIK3CA—hematologic cancer	1.62e-05	0.000215	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CREB1—hematologic cancer	1.61e-05	0.000214	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MDM2—hematologic cancer	1.61e-05	0.000214	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NOTCH1—hematologic cancer	1.6e-05	0.000213	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—BRAF—hematologic cancer	1.59e-05	0.000211	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCL2—hematologic cancer	1.58e-05	0.00021	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAP2K1—hematologic cancer	1.58e-05	0.000209	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL6R—hematologic cancer	1.57e-05	0.000209	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CREBBP—hematologic cancer	1.57e-05	0.000209	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CD80—hematologic cancer	1.57e-05	0.000209	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KIT—hematologic cancer	1.57e-05	0.000208	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CG—hematologic cancer	1.57e-05	0.000208	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—NRAS—hematologic cancer	1.57e-05	0.000208	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MTOR—hematologic cancer	1.57e-05	0.000208	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CB—hematologic cancer	1.57e-05	0.000208	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CD—hematologic cancer	1.57e-05	0.000208	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PIK3CA—hematologic cancer	1.55e-05	0.000206	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PTPN11—hematologic cancer	1.54e-05	0.000205	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—KRAS—hematologic cancer	1.53e-05	0.000203	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—MAPK3—hematologic cancer	1.5e-05	0.000199	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAP2K1—hematologic cancer	1.5e-05	0.000199	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—FGF2—hematologic cancer	1.5e-05	0.000199	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—HRAS—hematologic cancer	1.5e-05	0.000199	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CREB1—hematologic cancer	1.49e-05	0.000198	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CD—hematologic cancer	1.49e-05	0.000198	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3R1—hematologic cancer	1.48e-05	0.000196	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PIK3CA—hematologic cancer	1.48e-05	0.000196	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—BRAF—hematologic cancer	1.48e-05	0.000196	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CDKN1B—hematologic cancer	1.47e-05	0.000195	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCL2—hematologic cancer	1.46e-05	0.000194	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—KRAS—hematologic cancer	1.46e-05	0.000194	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL6R—hematologic cancer	1.46e-05	0.000193	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—AKT1—hematologic cancer	1.46e-05	0.000193	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CREBBP—hematologic cancer	1.45e-05	0.000193	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CASP3—hematologic cancer	1.44e-05	0.000191	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL2—hematologic cancer	1.44e-05	0.000191	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—JAK2—hematologic cancer	1.44e-05	0.000191	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL6—hematologic cancer	1.43e-05	0.00019	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—FGF2—hematologic cancer	1.43e-05	0.000189	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PIK3CA—hematologic cancer	1.41e-05	0.000187	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3R1—hematologic cancer	1.41e-05	0.000187	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCND1—hematologic cancer	1.4e-05	0.000186	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MDM2—hematologic cancer	1.4e-05	0.000186	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—JUN—hematologic cancer	1.4e-05	0.000186	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAP2K1—hematologic cancer	1.39e-05	0.000184	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CD—hematologic cancer	1.38e-05	0.000183	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—JAK2—hematologic cancer	1.37e-05	0.000182	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PIK3CA—hematologic cancer	1.37e-05	0.000181	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MTOR—hematologic cancer	1.37e-05	0.000181	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CB—hematologic cancer	1.37e-05	0.000181	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CDKN1A—hematologic cancer	1.36e-05	0.00018	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PTEN—hematologic cancer	1.36e-05	0.00018	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—KRAS—hematologic cancer	1.35e-05	0.000179	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PIK3CA—hematologic cancer	1.34e-05	0.000178	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MDM2—hematologic cancer	1.34e-05	0.000177	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MAPK8—hematologic cancer	1.33e-05	0.000176	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—AKT1—hematologic cancer	1.32e-05	0.000175	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FGF2—hematologic cancer	1.32e-05	0.000175	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—HRAS—hematologic cancer	1.3e-05	0.000173	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3R1—hematologic cancer	1.3e-05	0.000173	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MTOR—hematologic cancer	1.3e-05	0.000172	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CB—hematologic cancer	1.3e-05	0.000172	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EP300—hematologic cancer	1.29e-05	0.000171	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CDKN1B—hematologic cancer	1.28e-05	0.00017	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—AKT1—hematologic cancer	1.27e-05	0.000168	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—JAK2—hematologic cancer	1.27e-05	0.000168	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SRC—hematologic cancer	1.26e-05	0.000167	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CASP3—hematologic cancer	1.26e-05	0.000167	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL2—hematologic cancer	1.25e-05	0.000166	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL6—hematologic cancer	1.25e-05	0.000165	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CA—hematologic cancer	1.24e-05	0.000165	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—HRAS—hematologic cancer	1.24e-05	0.000165	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MDM2—hematologic cancer	1.24e-05	0.000164	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—VEGFA—hematologic cancer	1.22e-05	0.000162	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCND1—hematologic cancer	1.22e-05	0.000162	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—JUN—hematologic cancer	1.22e-05	0.000162	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CDKN1B—hematologic cancer	1.22e-05	0.000162	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—STAT3—hematologic cancer	1.21e-05	0.000161	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NRAS—hematologic cancer	1.21e-05	0.00016	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—AKT1—hematologic cancer	1.21e-05	0.00016	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MTOR—hematologic cancer	1.2e-05	0.000159	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CB—hematologic cancer	1.2e-05	0.000159	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CASP3—hematologic cancer	1.2e-05	0.000159	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL2—hematologic cancer	1.19e-05	0.000158	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL6—hematologic cancer	1.19e-05	0.000158	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CDKN1A—hematologic cancer	1.18e-05	0.000157	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PTEN—hematologic cancer	1.18e-05	0.000156	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCND1—hematologic cancer	1.16e-05	0.000154	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—JUN—hematologic cancer	1.16e-05	0.000154	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MAPK3—hematologic cancer	1.16e-05	0.000154	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAPK8—hematologic cancer	1.15e-05	0.000153	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—AKT1—hematologic cancer	1.15e-05	0.000153	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—HRAS—hematologic cancer	1.15e-05	0.000152	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CDKN1B—hematologic cancer	1.13e-05	0.00015	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MYC—hematologic cancer	1.13e-05	0.000149	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CDKN1A—hematologic cancer	1.13e-05	0.000149	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EP300—hematologic cancer	1.13e-05	0.000149	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TGFB1—hematologic cancer	1.12e-05	0.000149	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PTEN—hematologic cancer	1.12e-05	0.000149	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—AKT1—hematologic cancer	1.12e-05	0.000148	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CASP3—hematologic cancer	1.11e-05	0.000147	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL2—hematologic cancer	1.1e-05	0.000146	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL6—hematologic cancer	1.1e-05	0.000146	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAPK8—hematologic cancer	1.1e-05	0.000146	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—AKT1—hematologic cancer	1.1e-05	0.000145	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SRC—hematologic cancer	1.09e-05	0.000145	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCND1—hematologic cancer	1.08e-05	0.000143	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—JUN—hematologic cancer	1.07e-05	0.000142	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EP300—hematologic cancer	1.07e-05	0.000142	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—VEGFA—hematologic cancer	1.07e-05	0.000141	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—STAT3—hematologic cancer	1.06e-05	0.00014	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NRAS—hematologic cancer	1.05e-05	0.00014	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SRC—hematologic cancer	1.04e-05	0.000138	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CDKN1A—hematologic cancer	1.04e-05	0.000138	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KRAS—hematologic cancer	1.04e-05	0.000138	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PTEN—hematologic cancer	1.04e-05	0.000138	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAPK8—hematologic cancer	1.02e-05	0.000135	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—VEGFA—hematologic cancer	1.01e-05	0.000135	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—AKT1—hematologic cancer	1.01e-05	0.000134	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAPK3—hematologic cancer	1.01e-05	0.000134	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—STAT3—hematologic cancer	1e-05	0.000133	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NRAS—hematologic cancer	1e-05	0.000133	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EP300—hematologic cancer	9.91e-06	0.000131	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MYC—hematologic cancer	9.8e-06	0.00013	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TGFB1—hematologic cancer	9.78e-06	0.00013	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SRC—hematologic cancer	9.64e-06	0.000128	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAPK3—hematologic cancer	9.6e-06	0.000127	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CA—hematologic cancer	9.56e-06	0.000127	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—VEGFA—hematologic cancer	9.39e-06	0.000124	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MYC—hematologic cancer	9.33e-06	0.000124	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TGFB1—hematologic cancer	9.31e-06	0.000123	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—STAT3—hematologic cancer	9.29e-06	0.000123	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NRAS—hematologic cancer	9.27e-06	0.000123	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TP53—hematologic cancer	9.25e-06	0.000123	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KRAS—hematologic cancer	9.06e-06	0.00012	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAPK3—hematologic cancer	8.88e-06	0.000118	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—HRAS—hematologic cancer	8.85e-06	0.000117	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MYC—hematologic cancer	8.63e-06	0.000115	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KRAS—hematologic cancer	8.62e-06	0.000114	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TGFB1—hematologic cancer	8.61e-06	0.000114	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL6—hematologic cancer	8.47e-06	0.000112	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CA—hematologic cancer	8.32e-06	0.00011	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TP53—hematologic cancer	8.05e-06	0.000107	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KRAS—hematologic cancer	7.98e-06	0.000106	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CA—hematologic cancer	7.92e-06	0.000105	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AKT1—hematologic cancer	7.81e-06	0.000104	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—HRAS—hematologic cancer	7.7e-06	0.000102	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TP53—hematologic cancer	7.66e-06	0.000102	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL6—hematologic cancer	7.37e-06	9.78e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CA—hematologic cancer	7.33e-06	9.72e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HRAS—hematologic cancer	7.33e-06	9.72e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TP53—hematologic cancer	7.09e-06	9.41e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL6—hematologic cancer	7.02e-06	9.31e-05	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AKT1—hematologic cancer	6.8e-06	9.02e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HRAS—hematologic cancer	6.78e-06	9e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL6—hematologic cancer	6.49e-06	8.61e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AKT1—hematologic cancer	6.47e-06	8.58e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AKT1—hematologic cancer	5.99e-06	7.94e-05	CbGpPWpGaD
